Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;7(2):90-7.
doi: 10.1038/nrclinonc.2009.214. Epub 2009 Dec 15.

Genomic Markers for Decision Making: What Is Preventing Us From Using Markers?

Affiliations
Review

Genomic Markers for Decision Making: What Is Preventing Us From Using Markers?

Vicky M Coyle et al. Nat Rev Clin Oncol. .

Abstract

The advent of novel genomic technologies that enable the evaluation of genomic alterations on a genome-wide scale has significantly altered the field of genomic marker research in solid tumors. Researchers have moved away from the traditional model of identifying a particular genomic alteration and evaluating the association between this finding and a clinical outcome measure to a new approach involving the identification and measurement of multiple genomic markers simultaneously within clinical studies. This in turn has presented additional challenges in considering the use of genomic markers in oncology, such as clinical study design, reproducibility and interpretation and reporting of results. This Review will explore these challenges, focusing on microarray-based gene-expression profiling, and highlights some common failings in study design that have impacted on the use of putative genomic markers in the clinic. Despite these rapid technological advances there is still a paucity of genomic markers in routine clinical use at present. A rational and focused approach to the evaluation and validation of genomic markers is needed, whereby analytically validated markers are investigated in clinical studies that are adequately powered and have pre-defined patient populations and study endpoints. Furthermore, novel adaptive clinical trial designs, incorporating putative genomic markers into prospective clinical trials, will enable the evaluation of these markers in a rigorous and timely fashion. Such approaches have the potential to facilitate the implementation of such markers into routine clinical practice and consequently enable the rational and tailored use of cancer therapies for individual patients.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Pharmacogenomics J. 2006 May-Jun;6(3):166-73 - PubMed
    1. J Histochem Cytochem. 2006 Nov;54(11):1229-37 - PubMed
    1. J Mol Med (Berl). 2009 Feb;87(2):211-24 - PubMed
    1. Cancer Invest. 2008 May;26(4):327-32 - PubMed
    1. J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 - PubMed

LinkOut - more resources

Feedback